Company / Cash & Equivalents
TENAX THERAPEUTICS, INC. Cash & Equivalents History
FY2012-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$94.9M
FY2024
5-year range
$783.5K / $94.9M
FY2020-FY2024
Trend
+1097.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +1097% YoY in FY2024, a notable deviation from the 4-year average annual change of +488%.
Based on SEC 10-K filings.
$95M in FY2024 with a 10-year CAGR of +48.0%.
Improved from $783,528 to $95M over the past 9 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- +48.0%
Key checks
Key Insights
- In FY2024, cash & equivalents increased 1097.3% year-over-year.
- Lowest cash & equivalents in the period was in FY2012.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.24 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $94.9M | +1097.3% |
| FY2016 | $7.9M | +911.6% |
| FY2015 | $783.5K | -58.3% |
| FY2014 | $1.9M | +0.0% |
| FY2013 | $1.9M | - |
| FY2012 | $0 | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026